Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

Cited by (1,110)

Items 801–900 of 1,110

1. Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta‐Analysis
   Giovanni Antonio Silverii, Valerio Velardi, Christian Marinelli, Antonino Lax, Matteo Monami, Edoardo Mannucci · 2026 · Diabetes Obesity and Metabolism
2. Metformin kullanımının akut iskemik inmede şiddet ve prognoz üzerine etkisi
   Tehran Allahverdiyev, Mine Hayriye Sorgun, Canan Togay Işıkay, Canan Yücesan · 2020 · Turkish Journal of Cerebrovascular Diseases
3. Abnormal Glucose Tolerance in Prediabetes Patients with Acute Myocardial Infarction: Implications for Therapy
   Nitchakarn Laichuthai, Ralph Anthony DeFronzo · 2021 · Journal of Endocrinological Science
4. Stroke prevention in diabetes with glucagon-like peptide-1 receptor agonists: A game-changer?
   Niki Katsiki, Vivian Andrew Fonseca · 2021 · Journal of Diabetes and its Complications
5. Alogloptin and pioglitazone. Perspectives of combined administration
   Tatiana Yu. Demidova, A. S. Kochina · 2021 · Endocrinology News Opinions Training
6. Diabetes and Cerebrovascular Disease
   Vasileios‐Arsenios Lioutas, Lina Palaiodimou · 2023 · Contemporary cardiology
7. A pioglitazon újrafelfedezése
   Bence Pokoly, Anikó Somogyi · 2023 · Orvosi Hetilap
8. Type 2 diabetes mellitus, non-alcoholic fatty liver disease and cardiovascular disease: causal relationships and the role of anti-diabetic drugs
   Tatiana Yu. Demidova, Д. В. Скуридина, E. S. Pervushina · 2023 · FOCUS Endocrinology
9. Current options for the treatment of obesity
   Martin Haluzı́k, Iva Jakubíková, Michaela Kudláčková, Luděk Horváth · 2023 · Medicína pro praxi
10. Stroke Prevention by Antihyperglycemic Drugs in Type 2 Diabetes Mellitus
    Stewart Gary Albert, Ekta Shrestha, Vaishaliben Ahir · 2023 · Endocrine Practice
11. Association Apo B/Apo a-1 Ratio and Prognostic Nutritional Index with 90-Day Outcomes of Acute Ischemic Stroke
    Junqi Liao, Yuan Zhu, Aimei Zhang et al. · 2024 · Diabetes Metabolic Syndrome and Obesity
12. The User’s Guide to the Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
    Sonia Butalia, HARPREET SINGH BAJAJ, Rahul Jain, Karen Leung, Kerry D. Mansell, Sonja M. Reichert, Peter Alexander Senior, Baiju R. Shah · 2024 · Canadian Journal of Diabetes
13. EPA but not DHA improve systemic IR through activating muscle IL-6/AMPK pathway in high-fat diet-fed mice
    Lianzhi Mao, Qunying Xie, Qiting Cheng, Wei Tang, Limei Mao · 2025 · Journal of Functional Foods
14. Cerebrovascular disease
    2025
15. Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus – Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßchirurgie und Gefäßmedizin (DGG)
    Bernd M. Balletshofer, Dittmar Böckler, Holger Diener, Jörg Heckenkamp, Wulf D. Ito, Marcus Katoh, Holger Lawall, Nasser M. Malyar, Yves Oberländer, Peter Reimer et al. · 2020 · Diabetologie und Stoffwechsel
16. Stroke prevention in patients with type 2 diabetes mellitus or prediabetes: recommendations of the Spanish Society of Neurology’s Stroke Study Group
    Blanca Fuentes, Sergio Amaro, M. Alonso de Leciñana, Juan Francisco Arenillas, Óscar Ayo Martín, Mar Castellanos, M. Freijo, García-Pastor, Meritxell Gomis, M. Gómez Choco et al. · 2021 · Neurología (English Edition)
17. A Diagnostic Score for Insulin Resistance in Nondiabetic Patients with Ischemic Stroke or Transient Ischemic Attack
    Jin Xu, Catherine M. Viscoli, Gary A. Ford, Mark Gorman, Walter N. Kernan · 2016 · Journal of Stroke and Cerebrovascular Diseases
18. Insulin Resistance Intervention After Stroke Trial of Pioglitazone
    George Ntaios, Thomas A. Kent · 2016 · Stroke
19. α-Glukosidase-Hemmer und Thiazolidindione (Glitazone)
    Werner Alfons Scherbaum · 2016 · Der Diabetologe
20. Need for Outcome Scenario Analysis of Clinical Trials in Diabetes
    Rosa García-Verdugo, Michael Erbach, Oliver Schnell · 2016 · Journal of Diabetes Science and Technology
21. Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits
    Ruth Madievsky · 2018 · The Permanente Journal
22. Diabetes mellitus inhibits complete recanalization in patients with middle cerebral artery occlusion
    Junya Aoki, Kazumi Kimura, Naomi Morita · 2018 · Neurological Research
23. New insights into the older hypoglycemic agents in type 2 diabetes therapy
    Min Cao, Zachary T. Bloomgarden · 2020 · Journal of Diabetes
24. Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential
    Lucia Brodosi, Alessandra Musio, Francesca Alessandra Barbanti, Dorina Mita, Giulio Marchesini, Maria Letizia Petroni · 2020 · Hepatoma Research
25. Association between fasting blood glucose and intracranial cerebral artery stenosis: a secondary analysis based on a retrospective cross-sectional study in Korean adults
    Dan Wu, Danghan Xu, Ye Fan, Nuo Xu, Taotao Yao, Muxi Liao · 2021 · Acta Diabetologica
26. Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement
    Ansu Basu, Dipesh Patel, Peter H. Winocour, Bob Ryder · 2021 · British Journal of Diabetes
27. Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial
    Fang Zhang, Lizhi Tang, Jing Li, Zhe Yan, Juan Li, Nanwei Tong · 2021 · Diabetes Metabolic Syndrome and Obesity
28. Diabetes and Stroke
    Junghyun Noh · 2021 · Journal of Korean Diabetes
29. The Glycemic, Cardiovascular and Hepatic Outcomes of Pioglitazone Treatment: Evidence for Its Increased Use
    Mayer B. Davidson · 2020
30. Analysis of the formation of dysglycemia in the substantiation of early pathogenetic therapy of diabetes mellitus
    Lyudmila Alexandrovna Ruyatkina, D. S. Ruyatkin, I. S. Iskhakova · 2021 · Meditsinskiy sovet = Medical Council
31. Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
    Marina Vladimirovna Shestakova, Mikhail Borisovich Antsiferov, Ametov As, Gagik Radikovich Galstyan, Tatiana Yu. Demidova, Ashot Musaelovich Mkrtumyan, Nina Alexandrovna Petunina · 2021 · Diabetes Mellitus
32. Advances in Pharmacotherapeutics, Metabolic Surgery, and Technology for Diabetes
    Alfredo Daniel Guerron, Georgia M. Davis, Francisco J. Pasquel · 2021 · Endocrinology and Metabolism Clinics of North America
33. Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes
    Carolina Solis‐Herrera, Eugênio Cersósimo, Curtis L. Triplitt · 2021 · Diabetes Spectrum
34. In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome
    Maksim Khotimchenko, Nicholas E. Brunk, Mark S. Hixon, Daniel M. Walden, Hypatia Hou, Kaushik Chakravarty, Jyotika Varshney · 2022 · Pharmaceutical Research
35. Quality of Care Among Patients with Diabetes and Cerebrovascular Disease. Insights from The Diabetes Collaborative Registry
    Justin Basile Echouffo-Tcheugui, Alexander Turchin, Robert S. Rosenson, Gregg C. Fonarow, Abhinav Goyal, James A. de Lemos, Suzanne V. Arnold · 2022 · The American Journal of Medicine
36. The role of pioglitazone in the fight against insulin resistance, atherosclerosis, cardiovascular disease, and non-alcoholic fatty liver disease
    Nina Alexandrovna Petunina, Гончарова Екатерина Валерьевна, И. А. Кузина, Л. В. Недосугова, Мартиросян Нарине Степановна, Тельнова Милена Эдуардовна · 2022 · Diabetes Mellitus
37. Current management of diabetes patients with COVID-19
    Arup Kumar Misra, Gaurav Manikrao Rangari, C Madhavrao, Sushil Kumar Sharma · 2023 · Expert Review of Endocrinology & Metabolism
38. Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus
    Bernd M. Balletshofer, Dittmar Böckler, Holger Diener, Jörg Heckenkamp, Wulf D. Ito, Marcus Katoh, Holger Lawall, Nasser M. Malyar, Hui Jing Qiu, Peter Reimer et al. · 2023 · Die Diabetologie
39. Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan
    Chin‐Hsiao Tseng · 2023 · Cancers
40. Effect of pioglitazone on vascular events in post-stroke cognitive impairment: Post hoc analysis of the IRIS trial
    Kat Schmidt, Melinda C. Power, Adam Ciarleglio · 2023 · International Journal of Stroke
41. Long-term results of transferring the patient from therapy with glucagon-like peptide-1 receptor agonists in combination with metformin to a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone and inhibitor of type 2 sodium-glucose cotransporter in type 2 diabetes
    В. В. Салухов, Д. А. Шипилова, Alexey A. Minakov · 2024 · Diabetes Mellitus
42. Association between Smoking Habit Changes and the Risk of Myocardial Infarction in Ischemic Stroke Patients: A Nationwide Cohort Study
    Dae Young Cheon, Kyungdo Han, Dong A Ye, Yeon Jung Lee, Jeen Hwa Lee, Jae Hyuk Choi, Sook Jin Lee, Seongwoo Han, Myung Soo Park, Minwoo Lee · 2024 · Neuroepidemiology
43. Stroke: Secondary prevention of ischemic events.
    Jane G. Morris, Emily L Carter, Stephen A. Martin · 2017 · PubMed
44. Physiopathological Treatment Approach and Position of Pioglitazone in Type 2 Diabetes
    Abdülhalim Şenyiğit, Mustafa Kanat · 2017 · Anadolu Kliniği Tıp Bilimleri Dergisi
45. Quantification of Insulin Action in Human Subjects
    Andrew J. Krentz, Christian Weyer, Marcus Hompesch · 2019 · Springer eBooks
46. SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins
    Awadhesh Kumar Singh, Ritu Singh · 2019 · Indian Journal of Endocrinology and Metabolism
47. Risk Factors and Sociodemographic Characteristics of Ischemic Stroke in Brazil – A Systematic Review
    Cristianne Confessor Castilho Lopes, Eduardo Barbosa Lopes, Lucas Castilho Lopes, Vanessa da Silva Barros, Viviane Dorgievicz, Marivane Lemos, Daniela dos Santos, Paulo Sérgio da Silva, Youssef Elias Ammar, Heliude de Quadros e Silva et al. · 2020 · International Journal of Advanced Engineering Research and Science
48. Glycaemic Control in Diabetes
    Dirk Müller‐Wieland, Julia Brandts, Marlo Verket, Nikolaus Marx, Katharina S. Schütt · 2021 · Handbook of experimental pharmacology
49. Transient Ischemic Attack
    Murat Güntel · 2021 · Advances in medical technologies and clinical practice book series
50. Reducing the impact of stroke and improving public health
    Graeme J. Hankey, Philip B. Gorelick · 2019 · Warlow's Stroke
51. Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684–1692
    Niki Katsiki, Dimitri P. Mikhailidis · 2017 · Diabetes Care
52. Pioglitazone versus sulfonylureas: cardiovascular outcomes with older diabetes drugs
    Vivian Andrew Fonseca, Dragana Lovre · 2017 · The Lancet Diabetes & Endocrinology
53. Aim to normalize glucose levels and reduce cardiovascular mortality when managing type 2 diabetes in the elderly
    Adis Medical Writers · 2019 · Drugs & Therapy Perspectives
54. Alimentazione, salute e longevità nei pazienti adulti
    Guest Editors P. Gnerre, R Frediani, Roberto Risicato, Massimo Rondana, Roberto Nardi · 2019 · Italian Journal of Medicine
55. Periodization of the brain ischemic insult
    К. В. Серіков, L. M. Smyrnova · 2019 · Klinicheskaia khirurgiia
56. Differential associations between pre-diabetes, diabetes and stroke occurrence among West Africans
    Fred Stephen Sarfo, Bruce I Ovbiagele, Joshua Odunayo Akinyemi, Onoja Matthew Akpa, Albert Kwaku Akpalu, Kolawole Wahab, Godwin Inalegwu Ogbole, Reginald Obiako, Morenikeji Adeyoyin Komolafe, Lukman Femi Owolabi et al. · 2022 · Journal of Stroke and Cerebrovascular Diseases
57. The association between pioglitazone consumption and incidence of bladder cancer in type II diabetic patients: a systematic review and meta-analysis of observational studies
    Pantea Ramezannezhad, Mohammadreza Khosravifarsani · 2023 · Journal of Nephropathology
58. Pioglitazone in spontaneous subarachnoid hemorrhage: study protocol of a multicenter, double-blind, randomized trial (PSSH)
    Junhui Chen, Mingchang Li, Lei Chen et al. · 2024 · Frontiers in Pharmacology
59. Stroke Survivors With Type 2 Diabetes: Repositioning Pioglitazone in an Era Dominated by Gliflozins
    Navin Suthahar · 2025 · Mayo Clinic Proceedings
60. Treatment of type 2 diabetes mellitus - a current view of the different drug classes and strategies for their use
    Jan Brož · 2025 · Vnitřní lékařství
61. Nuclear receptors in pulmonary hypertension: From pathophysiological mechanisms to clinical implications
    Tianxin Xiong, Yi Li, Hong Chen, Ding‐Sheng Jiang, Xin Yi · 2025 · Cytokine & Growth Factor Reviews
62. Daqinjiao Decoction Ameliorates CSVD via RXR‐γ/PPAR‐γ/VEGF‐α Pathway: Insights From Transcriptome Sequencing and Network Pharmacology
    Mengna Lv, Xiao-Lu Yang, Xiaolu Shi, Shengxuan Cao, Wenjie Li, Mingmei Zhou, Xiaojun Gou, Ying Huang · 2025 · Journal of Cellular and Molecular Medicine
63. Decades old glitazones still find niche in drug discoveries as PPAR-γ agonists: medicinal chemistry perspective, structure-activity relationships and therapeutic implications
    P. Archana, Thirumoorthy Durai Ananda Kumar, N. Vijaya Ganesh, Manal Mohammed, Harshal Pundalik Tavanoji, R Deepikarani, B. R. Prashantha Kumar · 2025 · Bioorganic & Medicinal Chemistry
64. Pioglitazone as Add-On to Metformin and Dapagliflozin Yields Significant Enhancements in Glycemic Control in Poorly Controlled Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Sara Sabbagh, Ahmed Hegazy, Ahmed Adel, Abdullah Ali, Mohamed Alquddosy, Sara Khalid, Abdallah M Ibrahim, Ahmed Mohamed, Abdelrahman Mostafa, Ahmed Hassan et al. · 2025 · Cureus
65. The role of the PPAR system in diabetic cardiovascular risk and beyond
    Massimiliano Ruscica, Chiara Macchi, Alberto Corsini · 2025 · Current Opinion in Endocrinology Diabetes and Obesity
66. Gc inhibition preserves insulin sensitivity and reduces body weight without loss of muscle mass
    Richard Gill, Taiyi Kuo · 2025 · JCI Insight
67. PPAR-γ activation by pioglitazone inhibits microglia-mediated neuroinflammation and alleviates disease in neuromyelitis optica spectrum disorders
    Leung-Wah Yick, Ethel Yin-Ying Chan, Wenying Zou, Krystal Xiwing Yau, Jason Kwan, Chi Yan Lee, Koon Ho Chan · 2025 · Acta Neuropathologica Communications
68. Stroke medicine: what’s next?
    Yongjun Wang, Bowei Zhang, Xuewei Xie · 2025 · Stroke and Vascular Neurology
69. Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management
    Graziano Riccioni, Chiara Notarangelo, Mario Riccioni, Nicolantonio D’Orazio · 2025 · International Journal of Molecular Sciences
70. Therapeutic Potential of Saikosaponins in MASLD and Cross‐Organ Protection: A Research Update
    Jiayao Xiong, Wanyan Tan, Ze Jin, Xiangyu Li, Yifa Chen, Wanting Xie · 2026 · Food Science & Nutrition
71. Intracellular Pharmacokinetics of Antidiabetic Drugs: A Focused Narrative Review of Subcellular Distribution (2015–2025)
    Duaa Abdullah Bafail · 2026 · Diseases
72. Kardiovaskuläre Erkrankungen und Herzinsuffizienz bei Diabetes: Diagnostik und Management (Update 2026)
    Matthias Wolfgang Heinzl, Michael Resl, Julian Maier, Clemens Steinwender, Jürgen Falkensammer, Paul Fellinger, Thomas Steinmaurer, Christoph H. Saely, Friedrich Hoppichler, Harald Stingl et al. · 2026 · Wiener klinische Wochenschrift
73. Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study
    Shashank Joshi, Shambo Samrat Samajdar, Arvind Gupta, Mithun Bhartia, Sailesh Lodha, Supratik Bhattacharyya, Krishna G. Seshadri, Lakshmi Nagendra, A. G. Unnikrishnan, DAKSHATA A. PADHYE et al. · 2026 · Frontiers in Clinical Diabetes and Healthcare
74. Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes
    Helmut O. Steinberg · 2016 · Postgraduate Medicine
75. Is diabetes still a state of premature cardiovascular death?
    Miles Fisher · 2016 · Practical Diabetes
76. Cardiovascular Events in Company Employees Occur in Non-obese People without Metabolic Syndrome
    Kyoichi Mizuno, Takeshi Yamashita, Keiko Ohara · 2017 · Health Evaluation and Promotion
77. Targeting mitochondrial pyruvate carrier in nonalcoholic steatohepatitis: Growing evidence and future challenges
    Giovanni Musso, Roberto Gambino · 2017 · Hepatology
78. Nonglycemic Outcomes of Antidiabetic Medications
    Christopher Morse, David Sze, Dhiren K Patel, Jennifer D. Goldman · 2018 · Clinical Diabetes
79. Pioglitazone Decreased Bone Mineral Density and Bone-Specific Alkaline Phosphatase: A Systematic Review and Meta-analysis
    Taohua Sun, Taishan Yan, Yan Mei Zhao · 2019 · American Journal of Therapeutics
80. Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity
    Connie B. Newman, Katherine H. Saunders, Savitha Subramanian · 2021 · Elsevier eBooks
81. Feasibility trial of metformin XR in people with pre-diabetes and stroke (MIPPS)-randomised open blinded endpoint controlled trial
    Marjan Tabesh, Mariam Hachem, Lik‐Hui Lau et al. · 2021 · Journal of Clinical Neuroscience
82. Blood glucose, antidiabetic drugs, and risk of stroke
    Meng Lee, Bruce I Ovbiagele · 2021 · Precision and Future Medicine
83. Oral Therapies for Type 2 Diabetes
    Josivan Gomes Lima, Lúcia Helena Coelho Nóbrega, Natália Nóbrega de Lima · 2022 · Springer eBooks
84. Latest clinical research
    Mark Greener · 2016 · Independent Nurse
85. Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus – Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßchirurgie und Gefäßmedizin (DGG)
    Bernd M. Balletshofer, Dittmar Böckler, Holger Diener, Jörg Heckenkamp, Wulf D. Ito, Marcus Katoh, Holger Lawall, Nasser M. Malyar, Hui Jing Qiu, Peter Reimer et al. · 2022 · Diabetologie und Stoffwechsel
86. Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure
    Khawaja Muhammad Talha, Gregg C. Fonarow, Salim S. Virani, Javed Butler · 2022 · Methodist DeBakey Cardiovascular Journal
87. Effects of a Province-wide Triaging System for TIA
    Thomas Jeerakathil, Amy Yu, Philip M. C. Choi, Shoufan Fang, Ashfaq M Shuaib, Sumit R. Majumdar, Andrew M. Demchuk, Kenneth Butcher, T. Joseph Watson, Naeem Dean et al. · 2023 · Neurology
88. Complex metabolic–endocrine syndromes: associations with cardiovascular disease
    Andrew J. Krentz · 2023 · Elsevier eBooks
89. PPARs and Their Emerging Role in Vascular Biology, Inflammation and Atherosclerosis
    Javier Balda, Argyro Papafilippaki, Michael Johnstone, Jorge Plutzky · 2023 · Contemporary cardiology
90. The Metabolic Syndrome and Vascular Disease
    Michael A. Via, Jeffrey Ian Mechanick · 2023 · Contemporary cardiology
91. The PPAR System in Diabetes
    Jean-Claude Ansquer · 2023 · Contemporary diabetes
92. Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus – Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßchirurgie und Gefäßmedizin (DGG)
    Bernd M. Balletshofer, Dittmar Böckler, Holger Diener, Jörg Heckenkamp, Wulf D. Ito, Marcus Katoh, Holger Lawall, Nasser M. Malyar, Hui Jing Qiu, Peter Reimer et al. · 2023 · Diabetologie und Stoffwechsel
93. Results of Phase III Clinical Trial: a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Direkord in Ischemic Stroke Patients in Early Recovery Period
    Помыткин Игорь Анатольевич, В. В. Писарев, Меркулов Михаил Евгеньевич, L. V. Lukinykh, M. V. Morzhukhina, N. N. Karkischenko · 2023 · Journal Biomed
94. NAFLD, the hepatic manifestation of the metabolic syndrome
    Tirthankar Chaudhury, Lucia Brodosi, Giulio Marchesini, Sandip Kumar Mitra, Maria Letizia Petroni · 2024 · Elsevier eBooks
95. What is the role of pioglitazone for patients with type 2 diabetes in value-based care settings?
    Andrea Bush, Tina Benny, Genevieve Marie Hale, Matthew J. Seamon · 2024 · Drugs & Therapy Perspectives
96. Mediating effect of diabetes on the relationship between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease: a prospective cohort study
    Yuan Wei, Ying Ran, Jierui Wang, Fei Pei, Liufu Cui, Shuohua Chen, Shouling Wu, Lu Zhou · 2024 · European Journal of Gastroenterology & Hepatology
97. Prediabetes: A Benign Intermediate Stage or a Risk Factor in Itself?
    Irfan G Mulla, Ashish Prakash Anjankar, Shilpa Aditya Pratinidhi, Sarita V Agrawal, Deepak Gundpatil, Sandip Deepak Lambe · 2024 · Cureus
98. Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus
    Bernd M. Balletshofer, Dittmar Böckler, Holger Diener, Jörg Heckenkamp, Wulf D. Ito, Marcus Katoh, Holger Lawall, Nasser M. Malyar, Hui Jing Qiu, Peter Reimer et al. · 2024 · Diabetologie und Stoffwechsel
99. A New Treatable Risk Factor for Stroke and Atherosclerotic Cardiovascular Disease?
    Steven K. Feske · 2017 · Journal of the American College of Cardiology
100. Response by Lee et al to Letter Regarding Article, “Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis”
     Meng Lee, Jeffrey L. Saver, Bruce Ovbiagele · 2017 · Stroke